SCHEMBL1107221

SCHEMBL1107221

CCS(=O)(=O)Nc1cc2ccccc2s1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA2 P00918 2/20 0.45
CYP2A6 P11509 4/20 0.44
ADRB2 P07550 1/20 0.44
SLC9A1 P19634 1/20 0.43
RAB9A P51151 1/20 0.41
PSIP1 O75475 1/20 0.41
HDAC3 O15379 1/20 0.40
HDAC4 P56524 1/20 0.40
HDAC1 Q13547 1/20 0.40
HDAC7 Q8WUI4 1/20 0.40
HDAC2 Q92769 1/20 0.40
HDAC10 Q969S8 1/20 0.40
HDAC11 Q96DB2 1/20 0.40
HDAC8 Q9BY41 1/20 0.40
HDAC6 Q9UBN7 1/20 0.40
HDAC9 Q9UKV0 1/20 0.40
HDAC5 Q9UQL6 1/20 0.40
ASIC3 Q9UHC3 1/20 0.40
LOXL2 Q9Y4K0 1/20 0.40
CA1 P00915 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17687386 0.83 CA2 (0.47) CA2CYP2A6ADRB2SLC9A1HDAC3
SCHEMBL10280386 0.81 BCL2L1 (0.45) CA2CYP2A6ADRB2SLC9A1RAB9A
SCHEMBL2060857 0.81 SLC9A1 (0.40) CA2CYP2A6ADRB2SLC9A1RAB9A
SCHEMBL1098417 0.77 LMNA (0.50) CA2HDAC1CA1CA9BCL2L1
SCHEMBL5732542 0.75 CYP2A6 (0.49) CA2CYP2A6ADRB2RAB9AHDAC3
SCHEMBL2321108 0.74 CYP2A6 (0.41) CA2CYP2A6ADRB2SLC9A1RAB9A
SCHEMBL1098738 0.73 BCL2L1 (0.46) CA2CYP2A6SLC9A1HDAC3HDAC4
SCHEMBL10927053 0.72 CYP2A6 (0.46) CA2CYP2A6ADRB2SLC9A1RAB9A
SCHEMBL9825632 0.72 RAB9A (0.47) CYP2A6ADRB2RAB9AHDAC3HDAC4
SCHEMBL2494058 0.72 CYP2A6 (0.53) CA2CYP2A6ADRB2RAB9AHDAC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9434711-B2 Sulfonamides as TRPM8 modulators JANSSEN PHARMACEUTICA, N.V. (BE) 2016-09-06 US disclosed
US-9434711-B2 Sulfonamides as TRPM8 modulators JANSSEN PHARMACEUTICA, N.V. (BE) 2016-09-06 US disclosed
US-20140315899-A1 SULFONAMIDES AS TRPM8 MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2014-10-23 US disclosed
US-20140315899-A1 SULFONAMIDES AS TRPM8 MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2014-10-23 US disclosed
US-8809327-B2 Sulfonamides as TRPM8 modulators JANSSEN PHARMACEUTICA, NV (BE) 2014-08-19 US disclosed
EP-2183239-B1 SULFONAMIDES AS TRPM8 MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2012-08-22 EP disclosed
US-20120190674-A1 SULFONAMIDES AS TRPM8 MODULATORS BRANUM SHAWN T (US) 2012-07-26 US disclosed
US-20120190674-A1 SULFONAMIDES AS TRPM8 MODULATORS BRANUM SHAWN T (US) 2012-07-26 US disclosed
US-8216547-B2 Radiolabelled TRP M8 receptor ligands JANSSEN PHARMACEUTICA NV (BE) 2012-07-10 US disclosed
US-8153682-B2 Sulfonamides as TRPM8 modulators JANSSEN PHARMACEUTICA, NV (BE) 2012-04-10 US disclosed
US-8153682-B2 Sulfonamides as TRPM8 modulators JANSSEN PHARMACEUTICA, NV (BE) 2012-04-10 US disclosed
EP-2320956-A2 RADIOLABELLED TRP M8 RECEPTOR LIGANDS Janssen Pharmaceutica N.V. (BE) 2011-05-18 EP disclosed
US-20100015053-A1 RADIOLABELLED TRP M8 RECEPTOR LIGANDS JANSSEN PHARMACEUTICA NV (BE) 2010-01-21 US disclosed
WO-2010009220-A2 RADIOLABELLED TRP M8 RECEPTOR LIGANDS JANSSEN PHARMACEUTICA NV (BE) 2010-01-21 WO disclosed
US-20090264474-A1 SULFONAMIDES AS TRPM8 MODULATORS JANSSEN PHARMACEUTICA, N.V. (BE) 2009-10-22 US disclosed
US-20090264474-A1 SULFONAMIDES AS TRPM8 MODULATORS JANSSEN PHARMACEUTICA, N.V. (BE) 2009-10-22 US disclosed
WO-2009012430-A1 SULFONAMIDES AS TRPM8 MODULATORS JANSSEN PHARMACEUTICA N.V. (BE) 2009-01-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100015053-A1 RADIOLABELLED TRP M8 RECEPTOR LIGANDS TRPM8, TRPM7, GPR68 CA2 1033/4885CYP2A6 2311/4885ADRB2 133/4885
US-20120190674-A1 SULFONAMIDES AS TRPM8 MODULATORS TRPM8, TRPM5, TRPM2 CA2 264/4885CYP2A6 2366/4885ADRB2 639/4885
US-20140315899-A1 SULFONAMIDES AS TRPM8 MODULATORS TRPM8, TRPM5, TRPM2 CA2 264/4885CYP2A6 2366/4885ADRB2 639/4885
US-20090264474-A1 SULFONAMIDES AS TRPM8 MODULATORS TRPM8, TRPM5, TRPM2 CA2 264/4885CYP2A6 2366/4885ADRB2 639/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.